Literature DB >> 33463059

Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeutics.

Shan Su1, Qian Wang1, Shibo Jiang1.   

Abstract

Entities:  

Year:  2021        PMID： 33463059      PMCID： PMC7803365          DOI： 10.1002/ctm2.284

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN： 2001-1326


× No keyword cloud information.
  16 in total

1.  Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity.

Authors:  Ji Wang; Peiyu Li; Yang Yu; Yuhong Fu; Hongye Jiang; Min Lu; Zhiping Sun; Shibo Jiang; Lu Lu; Mei X Wu
Journal:  Science       Date:  2020-02-21       Impact factor: 47.728

2.  COVID mink analysis shows mutations are not dangerous - yet.

Authors:  Smriti Mallapaty
Journal:  Nature       Date:  2020-11       Impact factor: 49.962

3.  Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.

Authors:  Lanying Du; Wanbo Tai; Yang Yang; Guangyu Zhao; Qing Zhu; Shihui Sun; Chang Liu; Xinrong Tao; Chien-Te K Tseng; Stanley Perlman; Shibo Jiang; Yusen Zhou; Fang Li
Journal:  Nat Commun       Date:  2016-11-22       Impact factor: 14.919

4.  Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study.

Authors:  Barnaby E Young; Siew-Wai Fong; Yi-Hao Chan; Tze-Minn Mak; Li Wei Ang; Danielle E Anderson; Cheryl Yi-Pin Lee; Siti Naqiah Amrun; Bernett Lee; Yun Shan Goh; Yvonne C F Su; Wycliffe E Wei; Shirin Kalimuddin; Louis Yi Ann Chai; Surinder Pada; Seow Yen Tan; Louisa Sun; Purnima Parthasarathy; Yuan Yi Constance Chen; Timothy Barkham; Raymond Tzer Pin Lin; Sebastian Maurer-Stroh; Yee-Sin Leo; Lin-Fa Wang; Laurent Renia; Vernon J Lee; Gavin J D Smith; David Chien Lye; Lisa F P Ng
Journal:  Lancet       Date:  2020-08-18       Impact factor: 79.321

5.  A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.

Authors:  Shuai Xia; Lei Yan; Wei Xu; Anurodh Shankar Agrawal; Abdullah Algaissi; Chien-Te K Tseng; Qian Wang; Lanying Du; Wenjie Tan; Ian A Wilson; Shibo Jiang; Bei Yang; Lu Lu
Journal:  Sci Adv       Date:  2019-04-10       Impact factor: 14.136

6.  Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.

Authors:  Tyler N Starr; Allison J Greaney; Sarah K Hilton; Daniel Ellis; Katharine H D Crawford; Adam S Dingens; Mary Jane Navarro; John E Bowen; M Alejandra Tortorici; Alexandra C Walls; Neil P King; David Veesler; Jesse D Bloom
Journal:  Cell       Date:  2020-08-11       Impact factor: 41.582

7.  Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.

Authors:  Shuai Xia; Meiqin Liu; Chao Wang; Wei Xu; Qiaoshuai Lan; Siliang Feng; Feifei Qi; Linlin Bao; Lanying Du; Shuwen Liu; Chuan Qin; Fei Sun; Zhengli Shi; Yun Zhu; Shibo Jiang; Lu Lu
Journal:  Cell Res       Date:  2020-03-30       Impact factor: 25.617

8.  Broad neutralization of SARS-related viruses by human monoclonal antibodies.

Authors:  Anna Z Wec; Daniel Wrapp; Andrew S Herbert; Daniel P Maurer; Denise Haslwanter; Mrunal Sakharkar; Rohit K Jangra; M Eugenia Dieterle; Asparouh Lilov; Deli Huang; Longping V Tse; Nicole V Johnson; Ching-Lin Hsieh; Nianshuang Wang; Juergen H Nett; Elizabeth Champney; Irina Burnina; Michael Brown; Shu Lin; Melanie Sinclair; Carl Johnson; Sarat Pudi; Robert Bortz; Ariel S Wirchnianski; Ethan Laudermilch; Catalina Florez; J Maximilian Fels; Cecilia M O'Brien; Barney S Graham; David Nemazee; Dennis R Burton; Ralph S Baric; James E Voss; Kartik Chandran; John M Dye; Jason S McLellan; Laura M Walker
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

9.  Learning from the past: development of safe and effective COVID-19 vaccines.

Authors:  Shan Su; Lanying Du; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2020-10-16       Impact factor: 78.297

10.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.

Authors:  Hongjing Gu; Qi Chen; Guan Yang; Lei He; Hang Fan; Yong-Qiang Deng; Shibo Jiang; Shihui Sun; Cheng-Feng Qin; Yusen Zhou; Yanxiao Wang; Yue Teng; Zhongpeng Zhao; Yujun Cui; Yuchang Li; Xiao-Feng Li; Jiangfan Li; Na-Na Zhang; Xiaolan Yang; Shaolong Chen; Yan Guo; Guangyu Zhao; Xiliang Wang; De-Yan Luo; Hui Wang; Xiao Yang; Yan Li; Gencheng Han; Yuxian He; Xiaojun Zhou; Shusheng Geng; Xiaoli Sheng
Journal:  Science       Date:  2020-07-30       Impact factor: 47.728
View more
  4 in total

1.  A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life.

Authors:  Qianyu Duan; Shuai Xia; Fanke Jiao; Qian Wang; Rui Wang; Lu Lu; Shibo Jiang; Wei Xu
Journal:  Viruses       Date:  2022-03-22       Impact factor: 5.818

2.  Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.

Authors:  Henry T Peng; Shawn G Rhind; Andrew Beckett
Journal:  JMIR Public Health Surveill       Date:  2021-04-07

3.  Two Opposing Roles of SARS-CoV-2 RBD-Reactive Antibodies in Pre-Pandemic Plasma Samples From Elderly People in ACE2-Mediated Pseudovirus Infection.

Authors:  Kyu-Young Sim; Gwang-Hoon Ko; So-Eun Bae; Kyu Yeong Choi; Jung Sup Lee; Byeong C Kim; Kun Ho Lee; Mi-Ryoung Song; Sung-Gyoo Park
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

4.  A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses.

Authors:  Yanxing Cai; Wei Xu; Jiayi Tang; Najing Cao; Qiaoshuai Lan; Lu Lu; Shibo Jiang
Journal:  Cell Biosci       Date:  2021-07-08       Impact factor: 7.133
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.